Revimmune Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

Revimmune General Information

Description

Developer of therapies for autoimmune diseases. The Company's lead antineoplastic technology employs a bioengineered poliovirus construct and targets cancerous central nervous cells with great specificity recombinant poliovirus therapy has the potential to significantly reduce or eliminate current chemotherapy side-effects while completely destroying abnormal cancerous tissue.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 324 South Hyde Park Avenue
  • Suite 350
  • Tampa, FL 33606
  • United States
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Acquirer
Accentia Biopharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 324 South Hyde Park Avenue
  • Suite 350
  • Tampa, FL 33606
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Revimmune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Revimmune‘s full profile, request access.

Request a free trial

Revimmune Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Revimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3065772-A1 Combinations of checkpoint inhibitors and therapeutics to treat cancer Active 05-Nov-2013
US-20150202291-A1 Combinations of checkpoint inhibitors and therapeutics to treat cancer Inactive 05-Nov-2013
US-20150273033-A1 Combinations of checkpoint inhibitors and therapeutics to treat cancer Inactive 05-Nov-2013
EP-3065772-A4 Combinations of checkpoint inhibitors and therapeutics to treat cancer Active 05-Nov-2013
CA-2929407-A1 Combinations of checkpoint inhibitors and therapeutics to treat cancer Pending 05-Nov-2013 A61F7/00
To view Revimmune’s complete patent history, request access »

Revimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Revimmune Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Revimmune‘s full profile, request access.

Request a free trial

Revimmune FAQs

  • When was Revimmune founded?

    Revimmune was founded in 2006.

  • Where is Revimmune headquartered?

    Revimmune is headquartered in Tampa, FL.

  • What is the size of Revimmune?

    Revimmune has 2 total employees.

  • What industry is Revimmune in?

    Revimmune’s primary industry is Biotechnology.

  • Is Revimmune a private or public company?

    Revimmune is a Private company.

  • What is Revimmune’s current revenue?

    The current revenue for Revimmune is .

  • Who are Revimmune’s investors?

    Johns Hopkins Technology Ventures and The Hopkins Capital Group have invested in Revimmune.

  • When was Revimmune acquired?

    Revimmune was acquired on 27-Feb-2007.

  • Who acquired Revimmune?

    Revimmune was acquired by Accentia Biopharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »